1. Home
  2. BBW vs LYEL Comparison

BBW vs LYEL Comparison

Compare BBW & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Build-A-Bear Workshop Inc.

BBW

Build-A-Bear Workshop Inc.

HOLD

Current Price

$38.57

Market Cap

492.5M

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$22.41

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBW
LYEL
Founded
1997
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
492.5M
556.1M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
BBW
LYEL
Price
$38.57
$22.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$67.71
$30.60
AVG Volume (30 Days)
326.0K
75.9K
Earning Date
05-28-2026
05-12-2026
Dividend Yield
2.43%
N/A
EPS Growth
5.00
N/A
EPS
3.99
N/A
Revenue
$357,866,000.00
$36,000.00
Revenue This Year
$5.63
N/A
Revenue Next Year
$4.62
$8,712.13
P/E Ratio
$9.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.10
$0.39
52 Week High
$75.77
$45.00

Technical Indicators

Market Signals
Indicator
BBW
LYEL
Relative Strength Index (RSI) 45.39 47.92
Support Level $38.37 $22.38
Resistance Level $40.16 $26.89
Average True Range (ATR) 1.42 1.62
MACD 0.53 0.07
Stochastic Oscillator 59.36 33.41

Price Performance

Historical Comparison
BBW
LYEL

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: